<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>114(12)</volume><submitter>Sorich MJ</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Proteinuria is a common adverse effect of vascular endothelial growth factor targeted agents, particularly in metastatic renal cell carcinoma (mRCC). However, risk factors for proteinuria are poorly defined.&lt;h4>Methods&lt;/h4>Data on 1392 mRCC patients using pazopanib or sunitinib were pooled from two Phase-III clinical trials. Risk factors and prognostic effect of on-therapy proteinuria were evaluated by Cox proportional hazards regression.&lt;h4>Results&lt;/h4>Any-grade (1-4) and grade 3/4 proteinuria incidence were 15.0% and 3.7%, respectively. Asian ethnicity, diabetes, baseline systolic blood pressure (SBP), pre-existing grade 1 proteinuria and prior nephrectomy were significant independent predictors of either any-grade or grade 3/4 proteinuria. Proteinuria, particularly gr</pubmed_abstract><journal>British journal of cancer</journal><pagination>1313-7</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4984472</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data.</pubmed_title><pmcid>PMC4984472</pmcid><pubmed_authors>Mangoni AA</pubmed_authors><pubmed_authors>Woodman RJ</pubmed_authors><pubmed_authors>Kichenadasse G</pubmed_authors><pubmed_authors>Sorich MJ</pubmed_authors><pubmed_authors>Rowland A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data.</name><description>&lt;h4>Background&lt;/h4>Proteinuria is a common adverse effect of vascular endothelial growth factor targeted agents, particularly in metastatic renal cell carcinoma (mRCC). However, risk factors for proteinuria are poorly defined.&lt;h4>Methods&lt;/h4>Data on 1392 mRCC patients using pazopanib or sunitinib were pooled from two Phase-III clinical trials. Risk factors and prognostic effect of on-therapy proteinuria were evaluated by Cox proportional hazards regression.&lt;h4>Results&lt;/h4>Any-grade (1-4) and grade 3/4 proteinuria incidence were 15.0% and 3.7%, respectively. Asian ethnicity, diabetes, baseline systolic blood pressure (SBP), pre-existing grade 1 proteinuria and prior nephrectomy were significant independent predictors of either any-grade or grade 3/4 proteinuria. Proteinuria, particularly gr</description><dates><release>2016-01-01T00:00:00Z</release><publication>2016 Jun</publication><modification>2026-05-01T03:45:38.592Z</modification><creation>2019-03-27T02:20:37Z</creation></dates><accession>S-EPMC4984472</accession><cross_references><pubmed>27228299</pubmed><doi>10.1038/bjc.2016.147</doi></cross_references></HashMap>